Citation: J. Fahy, Modifications in the "upper" or velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities, CUR PHARM D, 7(13), 2001, pp. 1181-1197
Citation: Bt. Hill, Vinflunine, a second generation novel Vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for futuremitotic blockers, CUR PHARM D, 7(13), 2001, pp. 1199-1212
Citation: F. Gueritte, General and recent aspects of the chemistry and structure-activity relationships of taxoids, CUR PHARM D, 7(13), 2001, pp. 1229-1249
Authors:
Augustyns, K
Amssoms, K
Yamani, A
Rajan, PK
Haemers, A
Citation: K. Augustyns et al., Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents, CUR PHARM D, 7(12), 2001, pp. 1117-1141
Citation: Jj. Cazzulo et al., The major cysteine proteinase of Trypanosoma cruzi: A valid target for chemotherapy of Chagas disease, CUR PHARM D, 7(12), 2001, pp. 1143-1156
Citation: Rm. De Lederkremer et Le. Bertello, Glycoinositolphospholipids, free and as anchors of proteins, in Trypanosoma cruzi, CUR PHARM D, 7(12), 2001, pp. 1165-1179
Citation: D. Alvarez et al., Cytokine therapeutics for asthma: An appraisal of current evidence and future prospects, CUR PHARM D, 7(11), 2001, pp. 1059-1081
Citation: M. Gharaee-kermani et Sh. Phan, Role of cytokines and cytokine therapy in wound healing and fibrotic diseases, CUR PHARM D, 7(11), 2001, pp. 1083-1103